National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 53969 [2021-21124]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 186 / Wednesday, September 29, 2021 / Notices
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Clinical Trial,
Large Scale Epidemiology and Secondary
Data Analysis Applications.
Date: October 20, 2021.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, National
Institute of Health, 6700B Rockledge Drive,
Suite 3400, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Jeanette M. Hosseini,
Ph.D., Scientific Review Officer, National Eye
Institute, National Institute of Health, 6700B
Rockledge Drive, Suite 3400, Bethesda, MD
20892, 301–451–2020, jeanetteh@
mail.nih.gov.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Mentored
Clinical Scientist Research Career
Development Award (K08 and K23).
Date: October 21, 2021.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, National
Institute of Health, 6700B Rockledge Drive,
Suite 3400, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Jennifer C. Schiltz, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
National Eye Institute, National Institute of
Health, 6700B Rockledge Drive, Suite 3400,
Bethesda, MD 20892, 240–276–5864,
jennifer.schiltz@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: September 23, 2021.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–21092 Filed 9–28–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
VerDate Sep<11>2014
18:22 Sep 28, 2021
Jkt 253001
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; NHLBI
Mentored Patient-Oriented Research Study
Section.
Date: November 4–5, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Stephanie Johnson Webb,
Ph.D., Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, National Institutes
of Health, 6705 Rockledge Drive, Room 208–
V, Bethesda, MD 20892, (301) 827–7992,
stephanie.webb@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: September 23, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–21124 Filed 9–28–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Leveraging Artificial Intelligence (AI) Tools
for Substance Use Disorders (SUD) Drug
Discovery and Development.
Date: November 4, 2021.
Time: 10:00 a.m. to 6:00 p.m.
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
53969
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Jenny Raye Browning,
Ph.D., Scientific Review Officer, Scientific
Review Branch Division of Extramural
Research, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443–4577,
jenny.browning@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Avant-Garde Award Program and Avenir
Award Program for HIV/AIDS and Substance
Use Disorder Research (DP1, DP2, Clinical
Trial Optional).
Date: November 30–December 1, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Yvonne Owens Ferguson,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 402–7371, yvonne.ferguson@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS).
Dated: September 23, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–21130 Filed 9–28–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
E:\FR\FM\29SEN1.SGM
29SEN1
]]>Agencies
[Federal Register Volume 86, Number 186 (Wednesday, September 29, 2021)]
[Notices]
[Page 53969]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-21124]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Heart, Lung, and Blood Initial Review Group;
NHLBI Mentored Patient-Oriented Research Study Section.
Date: November 4-5, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6705 Rockledge Drive,
Bethesda, MD 20817 (Virtual Meeting).
Contact Person: Stephanie Johnson Webb, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Room 208-V, Bethesda, MD 20892, (301) 827-7992,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: September 23, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-21124 Filed 9-28-21; 8:45 am]
BILLING CODE 4140-01-P
